About: Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months
Creator	Cruz, Oswaldo Paulo, São Roussy, Gustave Singh, Gupta, S Ades, F Alemão, Hospital Antwerp, Belgium Boyle, F Brajendra, Prasad Capelan, M Chia, Massard Christophe, Pattu De Azambuja, Brazil De Las Heras, B De, Begoña Frances, Boyle Grande, Grande, E Kamal, Heras Leone, Á Manuela, Leone Marta, Marco Mcnally, Mcnally, Á Monika, Portera Pattu, Á Portera, Á Pugazhenthi, Prasad Rajeev, Capelan Ramachandran, Venkitaraman Romano, Á Saini Histogenex, M Saini, K Saini, Lamba Saini, S Saini, Á Sudeep Gupta, Venkitaraman, Á
source	Medline; PMC
abstract	The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1007/s40487-020-00124-2
bibo:pmid	32749634
has license	cc-by-nc
sha1sum (hex)	82ed334c851c0f0cd0fc73d05322f50898ae13d9
schema:url	https://doi.org/10.1007/s40487-020-00124-2
resource representing a document's title	Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months
has PubMed Central identifier	PMC7402077
has PubMed identifier	32749634
schema:publication	Oncol Ther
resource representing a document's body	covid:82ed334c851c0f0cd0fc73d05322f50898ae13d9#body_text
is schema:about of	named entity 'Research' named entity 'HAVE' named entity 'critically ill' named entity 'higher' named entity 'malignancy' named entity 'COVID-19' named entity 'COVID-19 Pandemic' named entity 'significant impact' named entity 'Russia' named entity 'radionuclides' named entity 'TERAVOLT' named entity 'human society' named entity 'anti-CD20' named entity 'risk of death' named entity 'Italy' named entity 'Brazil' named entity 'clinical trials' named entity '95% CI' named entity 'New York' named entity 'human society' named entity 'targeted therapy' named entity 'significant effect' named entity 'Europe' named entity 'China' named entity 'COVID' named entity 'infection' named entity 'symptom' named entity 'United States' named entity 'immunotherapy' named entity 'clinical outcome' named entity '95% CI' named entity 'lung' named entity '5.04' named entity 'lactate dehydrogenase' named entity 'CFR' named entity 'Spain' named entity 'data sets' named entity 'COVID' named entity 'COVID' named entity 'Cancer care' named entity 'COVID-19' named entity 'SARS-CoV-2 outbreak' named entity 'hematological malignancies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software